Influenza is a major cause of worldwide morbidity and mortality through frequent seasonal
epidemics and infrequent pandemics. Morbidity and mortality rates from seasonal influenza …

The first clinical trial of an MF59®-adjuvanted influenza vaccine (Novartis) was conducted
20 years ago in 1992. The product that emerged (Fluad®, Novartis) was licensed first in Italy …

Antigen-specific mucosal immunity is thought to be important for protection against influenza
virus infection. Currently licensed parenteral influenza vaccines stimulate the production of …

Vaccines containing novel adjuvant formulations are increasingly reaching advanced
development and licensing stages, providing new tools to fill previously unmet clinical …

MF59 is a well-established, safe and potent vaccine adjuvant that has been licensed for
more than 13 years for use in an influenza vaccine focused on elderly subjects (Fluad® …

With the exception of alum, emulsion-based vaccine adjuvants have been administered to
far more people than any other adjuvant, especially since the 2009 H1N1 influenza …

Vaccinations are one of the most important preventive tools against infectious diseases.
Over time, many different types of vaccines have been developed concerning the antigen …

Use of highly pure antigens to improve vaccine safety has led to reduced vaccine
immunogenicity and efficacy. This has led to the need to use adjuvants to improve vaccine …

Clinical and post-licensure data have demonstrated that AS03-adjuvanted inactivated split
virion vaccines, many with reduced antigen content, are effective against influenza infection …

Adjuvants are included in vaccine formulations to enhance the immunogenicity and efficacy
of vaccines. MF59® is an oil-in-water emulsion adjuvant and licensed for use in pandemic …